RenalytixAI is developing two approaches to help diagnose potential illnesses or complications with a patient’s kidneys. The company is working on an artificial intelligence-infused test for the early detection of kidney disease and will help in the accurate management of kidney transplant rejection.

The firm recently reported raising $29 million in funding to support the development and commercialization of the two products. Following the successful completion of its fundraising on Nov. 6, 2018, RenalytixAI started trading publicly on AIM, a market of the London Stock Exchange.

"RenalytixAI now has the financial resources to drive advanced diagnostic development to improve the management and cost of kidney disease," James McCullough CEO of RenalytixAI, said in a release. "We are grateful to our investors and medical collaborators who are committed to reducing the impact of this disease."

RenalytixAI will launch its first diagnostic product KidneyIntelX in 2019, in collaboration with the Icahn School of Medicine at Mount Sinai.

In combining these different inputs to develop its products, RenalytixAI has the potential to a powerful model for the prediction of disease progression and drug/therapy response in individual patients. The company said it intends to submit KidneyIntelX for regulatory review by FDA.

In 2016, Vanderbilt Universityresearchers revealed their work on microchip filters that can help remove waste products and hopefully keep patients off dialysis. Each chip acts as a filter and can be inexpensively produced and precisely tailored to individual patient needs.